Completed OBSERVATIONAL NCT01192945

Non-interventional Study With Azacitidin (Vidaza®) (Piaza)

Piaza - Non-interventional Study on the Efficacy and Safety of Azacitidin (Vidaza®) in Patients With Myelodysplastic Syndromes (MDS, INT-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder)

Sponsor: iOMEDICO AG

Conditions AML CMMOL MDS

Updated 7 times since 2017 Last updated: Nov 12, 2015 Started: Jul 31, 2010 Primary completion: Dec 31, 2014 Completion: Nov 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on AML and CMMOL, this trial is completed. The trial is conducted by iOMEDICO AG and has accumulated 7 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

iOMEDICO AG

Data source: iOMEDICO AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Freiburg im Breisgau, Germany